Clinical outcome following stimulation with HMG versus highly purified HMG in patients undergoing ICSI

Foutouh, Ismail Aboul; Khattab, Sherif; Mohesn, Iman Abdel; Moaz, Mohamed; Al-Inany, Hesham

doi:10.1016/s1472-6483(10)60780-8

Cited by 5 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical pregnancy rate was not statistically different between both groups. The non-statistically significant difference in clinical pregnancy rate between the two gonadotrophin preparations was matching with other reported trials in the medical literature [5,6].…”

Section: Discussionsupporting

confidence: 85%

IVF Outcomes with Either Highly Purified FSH vs. Recombinant FSH in Down-Regulated Normogonadotrophic Women: A Prospective Comparative Study in a Developing Country and Meta-Analysis

Moustafa¹,

Abdelwahed²,

Abosekena³

et al. 2009

TOWHJ

View full text Add to dashboard Cite

Objective: In order to compare the use of highly purified (HP) follicle stimulating hormone (FSH) with recombinant FSH (recFSH) in a developing country, research should not only focus on clinical data, but also on the evidence available in the literature from previous trials. Study Design: We performed a prospective clinical trial with 118 infertile females undergoing IVF: HP-FSH (n = 59); recFSH (n = 59). In addition, we performed a meta-analysis of RCTs comparing currently available HP-FSH vs. recFSH. The primary outcomes for both studies were live-birth rate and rate of ovarian hyperstimulation. Results: In the clinical trial, the response to ovarian hyperstimulation was similar in both groups including the number of oocytes retrieved and the number of ampoules of gonadotrophins. The live birth rate per woman was 30.51% vs. 35.59% in the HP-FSH and recFSH treated groups respectively (P = 0.70). The rate of OHSS was 5.09% in the HP-FSH compared to 6.78% in the recFSH treated groups (P = 1.00). Regarding the meta-analysis, the live-birth (O.R= 1.30, 95% CI= 0.92 to 1.84) and OHSS rates (O.R= 1.14, 95% CI= 0.32 to 4.04) were not significantly different between the two groups. There was significantly less treatment days and total dose (IU) in the HP-FSH group compared with the rFSH group. Conclusion: HP-FSH yields similar clinical outcome to recFSH in terms of oocytes retrieved and live-birth rate.

show abstract

Section: Discussionsupporting

confidence: 85%

IVF Outcomes with Either Highly Purified FSH vs. Recombinant FSH in Down-Regulated Normogonadotrophic Women: A Prospective Comparative Study in a Developing Country and Meta-Analysis

Moustafa¹,

Abdelwahed²,

Abosekena³

et al. 2009

TOWHJ

View full text Add to dashboard Cite

show abstract

“…[ 11 ] Purity of urinary gonadotropins was further improved with technological advances including nanofiltration techniques, which resulted in the development of highly purified (HP) hormones. [ 10 12 ] The advantages of these preparations include lesser injection dose requirements, ability to be administered subcutaneously, reduction in batch-to-batch variability, improved efficiency, ease of the development of individualized protocols based on the patient's need, with better control of developing follicles, less risk of multiple pregnancies, and hyperstimulation. [ 9 ]…”

Section: Introductionmentioning

confidence: 99%

Urinary versus recombinant gonadotropins for ovarian stimulation in women undergoing treatment with assisted reproductive technology

Patki

Bavishi²,

Kumari³

et al. 2018

J Hum Reprod Sci

View full text Add to dashboard Cite

Globally, about 10%–15% couples are affected by infertility, with major role being played by the couple's lifestyle. Several gonadotropin preparations (urinary, purified urinary, recombinant, and biosimilars) are available for use. Purified urinary formulations offer numerous advantages over their predecessor, including lesser injection dose required, ability to be administered subcutaneously, less batch-to-batch variability, better efficacy, ability to individualize protocols as per patient's need, better control of developing follicles, less risk of multiple pregnancies, and hyperstimulation. Published results of Cochrane reviews and meta-analysis show no difference in efficacy or safety between urinary and recombinant gonadotropins. In the absence of any significant difference, cost plays an important role in deciding choice of gonadotropins. In this article, we have reviewed the results of comparative clinical trials, Cochrane analysis, and meta-analysis to derive consensus statements regarding efficacy, safety, and cost implications of urinary versus recombinant gonadotropin preparations.

show abstract

Letrozole combined with low dose highly purified HMG for ovulation induction in clomiphene citrate-resistant infertile Chinese women with polycystic ovary syndrome: a prospective study

Zhao

Ruan

Mueck

2017

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

Clinical outcome following stimulation with HMG versus highly purified HMG in patients undergoing ICSI

Cited by 5 publications

References 11 publications

IVF Outcomes with Either Highly Purified FSH vs. Recombinant FSH in Down-Regulated Normogonadotrophic Women: A Prospective Comparative Study in a Developing Country and Meta-Analysis

IVF Outcomes with Either Highly Purified FSH vs. Recombinant FSH in Down-Regulated Normogonadotrophic Women: A Prospective Comparative Study in a Developing Country and Meta-Analysis

Urinary versus recombinant gonadotropins for ovarian stimulation in women undergoing treatment with assisted reproductive technology

Letrozole combined with low dose highly purified HMG for ovulation induction in clomiphene citrate-resistant infertile Chinese women with polycystic ovary syndrome: a prospective study

Contact Info

Product

Resources

About